The prevalence of depression and anxiety in people living with HIV/AIDS (PLWHA) ranges from 7.2% to 71.9% and 4.5% to 82.3%, respectively. This wide variation is attributed to differences in sample size and characteristics, and methodology for assessment of anxiety and depression. Moreover, anxiety and depression increase the morbidity of HIV by poor adherence to treatment and various other significant mechanisms. Early identification and effective management of these disorders is associated with improved antiretroviral adherence and improved quality of life in PLWHA. Different treatment modalities, including pharmacological and nonpharmacological therapies, are used for the management of anxiety and depression in PLWHA. Benzodiazepines are indicated for short periods of time. Clonazepam and lorazepam are safe in terms of drug-drug interactions and may be preferred. Selective serotonin reuptake inhibitors are safer than tricyclic antidepressants. Though the different selective serotonin reuptake inhibitors are supposed to be equally effective, to avoid interactions with antiretrovirals, the better options are sertraline, citalopram, and escitalopram. Various nonpharmacological therapies, including cognitive behavior therapy, interpersonal therapy, supportive psychotherapy, cognitive-behavioral-oriented group psychotherapy, experiential group psychotherapy, cognitive-behavioral stress management, stress management interventions, cognitive remediation therapy, mindfulness-based therapy, and aerobic and resistance exercise have been reported to be useful in treating depression among PLWHA. However, definitive evidence to decide which nonpharmacological intervention is most beneficial for the management of anxiety and depression in PLWHA is still required.
Introduction
The human immunodeficiency virus (HIV) is transmitted through sexual intercourse (unprotected anal or vaginal) and blood contamination, as well as during pregnancy, childbirth, and breastfeeding from the mother. The virus infects cells of the immune system, thereby weakening it, as a result of which the individual becomes more susceptible to various infections. The World Health Organization (WHO) states that the infection can advance to a final stage in 10-15 years (antiretroviral drugs can slow down the process even further), known as the acquired immunodeficiency syndrome (AIDS). The diagnosis of HIV infection in people 18 months is defined by WHO as: positive HIV antibody testing, which is confirmed by a second HIV antibody test relying on different antigens or of different operating characteristics; and/or positive virological
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Neurobehavioral HIV Medicine 2016: 7 15-30 Depression Anxiety Impact", and "HIV Depression Anxiety Treatment". A Google search was done with the search term "HIV Depression Anxiety, Prevalence, Impact and Treatment". Only full articles were downloaded and included for this review. During the PubMed search, using the term "HIV Depression Anxiety prevalence" returned 336 articles; similarly, "HIV Depression Anxiety impact" returned 140 articles and "HIV Depression Anxiety treatment" returned 482 articles. This initial search was done without any restrictions on the year of publication or the type of article. All publications containing information on any of the following endpoints in relation to HIV patients were shortlisted: depression, anxiety, prevalence, impact, and management (treatment), and abstracts of the articles were read to screen them. Thereafter, the full text of the selected articles were reviewed; recently published articles were preferred over older ones, and many cross-references were also checked and the articles found. Articles were excluded if they were not written in English, were related to child and adolescent population, or were of unrelated findings. Official documents from the WHO were also screened; in addition, some other articles were identified through Google and from the personal knowledge of the authors. In total, the findings of ∼150 articles were reviewed.
Results Incidence
There were very few results relating to studies estimating the incidence of depression or anxiety. A study that analyzed a sample of 2,737 PLWHA reported that the incidence of depression was 2.2 per 100 person years. 17 Another study reported an incidence of 1.89 per 100 person years for depression and 1.27 per 100 person years for generalized anxiety. 18 Prevalence In contrast to the few studies estimating the incidence, there were abundant studies estimating the prevalence of depression and anxiety. We scrutinized ∼40 and 30 studies, respectively, for depression and anxiety prevalence. There was a wide range of differences on the prevalence across these studies, as summarized in Tables 1 and 2 for depression and anxiety, respectively. There was a problem regarding the use of different methodologies and different definitions. In a recent Nigerian study, depressive symptoms were present in at least 49% of PLWHA. 19 A psychiatric disorder was present in almost half of the 2,864 PLWHA, including 36% having depression and 16% with generalized anxiety disorder (GAD). Nearly 40% of subjects were using an illicit substance and 12% were drug dependent. 4 Prevalence of depression is found to be very high among PLWHA, as compared general population. 20, 21 An early meta-analysis reported that the prevalence of depression in PLWHA was ∼10% as against 5% in the general population. 16 The prevalence of depression and anxiety among people with HIV infection was quite variable across different recent studies. The prevalence rate of depression in HIV patients in different studies varied from 7.2% to 71.9% ( Table 1 ). The studies were from various countries and had varying sample sizes, different methodologies, and used different depression rating scales or questionnaires.
While treating PLWHA, comorbid anxiety is often missed and not treated. Anxiety is higher among PLWHA than in the general population. In studies conducted across the world, the prevalence of anxiety varied from 4.5% to 82.3% ( Table 2) . Newly diagnosed HIV patients who feel socially stigmatized or are under excessive stress because of their disease had a higher prevalence of anxiety. 22 The different prevalence rates of anxiety disorders may also depend upon the stage of the illness. 23 While unipolar depressive disorders are the most common mental disorder among PLWHA, the majority also suffered from comorbid psychiatric disorders, which most frequently included anxiety disorders, dysthymia, and substance use disorder. 24 Neurobehavioral HIV Medicine 2016:7 submit your manuscript | www.dovepress.com 
Stage of illness
There may be various stages of disease progression in the HIV infection and HIV/AIDS care continuum: diagnosis establishment, contact with HIV medical care, undergoing treatment, at the start of ART, and during adherence to ART. 63 Asymptomatic stage is less distressing, and a low prevalence may be attributable to this stage of HIV infections. A recent study on asymptomatic HIV patients found relatively low prevalence of only 6% and 7%, respectively, for depression and anxiety. This study also found significantly increased prevalence of adjustment disorder, alcohol dependence, and sexual dysfunction in asymptomatic PLWHA. 43 As the illness progresses further and CD4 + cell count declines, the prevalence of depression increases. 63, 64 Gender of the patients There are various direct and indirect factors linked to the susceptibility of females in the transmission of HIV/ AIDS. The problem is further compounded with females of developing countries having poor education, health, and hygiene. In one study, female sex workers in Bangladesh reported their inability to convince their sexual partner to have safe sex. 65 The rates of depression in females in the general population as well as among HIV patients with injectable drug use are higher than those in males. 66 There are also gender differences in the symptoms of depression. During depressive episodes, females more frequently reported somatic symptoms of anxiety, easy fatigability, hypochondriac symptoms, poor appetite, and insomnia. [67] [68] [69] The presence or absence of these items in any rating scales influences depression ratings across the genders. Two studies focusing on the gender of the patients and psychiatric disorders in PLWHA concluded that HIV-positive females had higher levels of anxiety and depression compared to males. 70, 71 However, two studies found opposite results. 72, 73 The relationship between the gender of the patients and anxiety and depression in PLWHA therefore needs further detailed evaluation. that anxiety symptoms were common in HIV patients, but the prevalence of syndromal anxiety disorders is similar to that in the general population. 76 More recent studies have revealed that anxiety and depressive symptoms occur signi ficantly more frequently in PLWHA compared to the general population. 54 The etiological factors to both anxiety and HIV include alcohol and substance abuse, males having sex with males, or males having a bisexual relationship. 77 Increased anxiety symptoms in PLWHA were associated with being a former smoker, HIV infection detected within the past year, persistent symptoms presenting for .7 days in the past 6 months, 54 pain, concurrent substance use disorder, minimal family support, and the spouse having AIDS. 78 In a study based in India, anxiety disorders were detected in 36% PLWHA, the majority of whom had GAD. The prevalence of anxiety disorders in this study was higher than that found in studies conducted in developed countries. 78 
Depression and HIV infection

Panic disorder
Panic disorder is a frequent comorbid diagnosis with other psychiatric disorders as well as in association with HIV infection. Various studies report that the prevalence of panic disorder in patients with HIV ranged from 11% to 16%. 4, [79] [80] [81] The prevalence of panic disorder is less in PLWHA with resolved grief compared to those with unresolved grief. 82 
GAD and phobic disorder
Prevalence of GAD among PLWHA in various studies ranged between 6.5% and 20%. 4, 80, 81, [83] [84] [85] Longitudinal studies suggested that the passage of time after the initial diagnosis was associated with a significant decrease in the prevalence of GAD. 81 Simple phobia was diagnosed in 9% of 190 PLWHA. 83 
Post-traumatic stress disorder
In a review of various studies, the prevalence rates of post-traumatic stress disorder (PTSD) were found to vary between 10.4% and 42.2% in PLWHA. 86 The reasons for the occurrence of comorbid PTSD and other anxiety disorders in PLWHA include the trauma of having a potentially fatal illness, stigma related to HIV/AIDS, and the high rates of exposure to traumatic events (physical or sexual assault, the death of a friend or close family member). 12, [87] [88] [89] [90] [91] [92] [93] Methodological issues
The 7.2%-71.9% prevalence for depression and 4.5%-82.3% for anxiety represent significant heterogeneity across various studies. This variance is probably due to the methodological and conceptual factors that differ across studies and the differences in various measuring tools to quantify depression and anxiety (Tables 1 and 2 ). There are various methodological issues related to the prevalence studies of anxiety and depression in PLWHA: difficulty in finding homogenous segments of the HIV population; defining depression or anxiety as symptoms or syndromal diagnosis; different diagnostic criteria used such as Diagnostic and Statistical Manual or International Classification of Diseases and their versions; and use of a rating scale that varies from self-reported symptom checklists to clinician-administered psychiatric ratings. 20 There may be some subgroups such as injection drug users, where a high prevalence of depression is found, independent of the HIV status. 94 Different studies have also included samples of different age ranges and gender and at different stages of the illness. Some studies enquired for the presence of any depressive symptoms cross-sectional or in the past 2 weeks, or past month, or past year, or lifetime. It is expected that the prevalence of depression will increase as the time frame is lengthened. 20 Impact HIV infection and psychiatric illness are significant related risk factors, as PLWHA suffer from psychiatric symptoms and disorders more frequently than the general population. On the other hand, in people with a severe psychiatric disorder, HIV infection occurs more often than in the general population. Studies indicate that prior psychiatric history and symptomatic HIV disease, but not asymptomatic HIV disease, are predictors of vulnerability for depression. 75 Various studies and reviews have found a bidirectional association between HIV infection and depression, which involves complex biological and psychosocial interaction. 95 This leads to two questions: 1) why does HIV infection lead to depression and anxiety; and 2) what does depression and anxiety do to HIV infection.
why HIV infection leads to depression and anxiety
Various factors have been identified across studies that can be grouped as psychosocial and biological factors causing depression and anxiety among patients with HIV. Immediately after being diagnosed with HIV, patients show an increase in psychological distress. Adjustment problems were expected among newly diagnosed HIV patients. 96 However, ∼71% of patients in one study sample were depressed for longer periods than the criterion for adjustment disorder. 97 The incidence of depression also increases with progression of HIV disease. 98, 99 Neurobehavioral HIV Medicine 2016:7 submit your manuscript | www.dovepress.com
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Stigma
Researchers have identified the stigma of HIV/AIDS as an important factor since stigma is found frequently with HIV/ AIDS and is correlated with depression, anxiety, and other psychosocial problems. [100] [101] [102] [103] Patients with a stigmatizing illness know how other people view them because of their illness. This is called perceived stigma. 104 Stigmatization leads to restricted social activities, and because of their status, they may start to agree with the negative stereotypes associated with the condition. This process is referred to as internalized stigma, 105 which ultimately leads to psychosocial distress, depression, and anxiety. 101, 106, 107 Stigma has been related to unsafe sex practices, 106 delay in seeking HIV/AIDS treatment, 108 poor retention in follow-up, 109 poor ART adherence, 110 poor utilization of HIV voluntary counseling and testing services, 111 and significantly more complaints of anxiety and depression. 102 
Biological model
It has been suggested that symptoms of anxiety and depression in PLWHA occur because of biological mechanisms. 112 A recent review 113 described how HIV can predispose infected individuals to depression by several interrelated mechanisms. These include inducing chronic elevation of cytokines through activation of microglia and astrocytes; decreasing monoaminergic function; inducing neurotoxicity, especially in dopaminergic neurons; and reducing brain-derived neurotrophic factor. These viral pathways interact with psychosocial factors to create the depressive state. 113 These mechanisms, which may be caused directly by the virus or by the psychological stress related to negative psychosocial impact of HIV diagnosis, may also induce the activation of hypothalamic-pituitary-adrenal axis and the sympathetic nervous system, which activate cellmediated immunity both in the periphery and the CNS. 114, 115 Anxiety and depression may also be associated with systemic immune dysregulation. 116 
Effects of antiretroviral drugs
Depression and anxiety have also been attributed to antiretroviral drugs. A systematic review revealed that compared to the general population, PLWHA on ART have a higher prevalence of anxiety and depression. 53 Neuropsychiatric symptoms attributed to antiretroviral drugs (mainly efavirenz) improved significantly following substitution with another drug (eg, nevirapine). 117, 118 what depression and anxiety do to HIV infection Depression causes various direct and indirect morbidities, which include suicidal behavior, 119 increased use of health care facilities, 120 and poor QoL. 80 It is important to identify depression among PLWHA, as depression is associated with increased chances of HIV transmission 121 and ART non adherence, [122] [123] [124] resulting in failure to suppress viral load 125 and increased HIV disease progression. [126] [127] [128] [129] There are other mechanisms caused by depression that lead to a faster progression of HIV infection to AIDS, such as elevated cortisol secretion 13 and HIV replication through an increase in norepinephrine secretion. 130 Even AIDS-related death, specifically in females, was associated with chronic depression. 64, 131 Depression and disease progression HIV infection and the disease progression have altered significantly since the beginning of highly active ART and combination ART (cART). A good outcome depends on the patient's adherence to the medication regimen. Presence of depression is associated with medication nonadherence, resulting in a poor HIV disease outcome. [132] [133] [134] It has been suggested that baseline depression does not influence treatment adherence, as it is affected by incident depression during the treatment period. 135 This indicates that impaired treatment adherence is due to the acute depression, which occurs as a reactive phenomenon rather than a preexisting or past history, or a predisposition for depression.
Management
After recognizing, measuring, and understanding depression and anxiety associated with HIV, treating these comorbid disorders is the next focus. It is important to remember that subsyndromal presentation is associated with poor self-care and adverse health outcomes in PLWHA. Therefore, it is also essential to treat sub-syndromal disorders. 125 Appropriate and adequate management of comorbid depression and anxiety in PLWHA will not only result in symptomatic improvement of a psychiatric disorder but also improve ART adherence and their QoL 136, 137 In addition, improved antiretroviral adherence may reduce depressive symptoms. 138 
Pharmacological intervention
Anxiolytics, hypnotics, antidepressants, psychostimulants, and hormones have been used for in the treatment of depression and anxiety in PLWHA.
Anxiolytics and hypnotics
Benzodiazepines (BZDs) are frequently prescribed for anxiety in PLWHA 139 despite the lack of studies assessing their anti-anxiety effects in PLWHA. 136 In people at risk of habituation, tolerance, and abuse, BZDs are indicated for short periods of time. Also, PLWHA are particularly sensitive to the side effects of BZDs, such as amnesia and paradoxical reactions (disinhibition, confusion, etc). 137 Both clonazepam and lorazepam lack active metabolites and are safe in terms of drug-drug interactions. These drugs are probably the BZDs of choice for HIV patients receiving antiretrovirals (ARVs). 140, 141 Unlike BZDs, buspirone shows no potential for dependence and tolerance, and sexual dysfunction and weight gain are rare. However, it is metabolized by CYP3A4 and is best avoided in PLWHA receiving protease inhibitors. 137, 142 Efficacy studies of buspirone on PLWHA are lacking. Nonbenzodiazepine hypnotics (eszopiclone, zopiclone, zolpidem, and zaleplon) have low dependence potential and avoid daytime sedation that may occur with BZDs, but are also metabolized by CYP3A4 and should be avoided in PLWHA receiving protease inhibitors. 141, 143 Antidepressants Selective serotonin reuptake inhibitors Though slightly less effective than tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs) are better tolerated and therefore, are more suitable for long-term therapy. 144 Most of the SSRIs have been evaluated in PLWHA. Fluoxetine reduced depressive symptoms significantly compared to placebo. 61 Significant reduction in depressive symptoms were demonstrated by other SSRIs, but comparative effectiveness of the different SSRIs was yet to be ascertained. 137, 149 Most SSRIs may be used in HIV-positive adults 145, 146 since the most common side effects include anxiety, agitation, akathisia, weight loss, and sexual dysfunction. 137 However, all SSRIs are metabolized by CYP450 isoenzymes, 147 so ARVs may affect their plasma levels. To avoid interactions with ARVs, the better options are sertraline, citalopram, and escitalopram. 148, 149 However, it should be kept in mind that the chance of serotonin syndrome is increased when SSRIs are given to PLWHA who are on ART. 150 Depressed PLWHA who are compliant with SSRIs not only show a reduction in symptoms of depression but also better adherence to highly active ART and improved laboratory parameters. 151 
Comparison of TCAs and SSRIs
Treatment with both paroxetine and imipramine resulted in significantly greater reduction in depression compared to placebo. 152 In a double-blind comparison in the treatment of depressed women with advanced HIV disease, the response rate was 63% and 50%, respectively, for fluoxetine and desipramine. 153 However, treatment with TCAs is associated with significantly more side effects. 152 Considering the fact that dry mouth is a frequent complaint among PLWHA, 154 TCAs should be used in this population with caution.
Specific issues with newer antidepressants
Nefazodone is useful in treating depression in PLWHA. 155 However, nefazodone-induced hepatitis is a known entity, and hence it should be used with care in PLWHA because of the frequent occurrence of viral hepatitis. Mirtazapine is also an effective antidepressant with the added benefit of decreasing nausea and increasing weight, and can be useful in HIV wasting disease. 156 Venlafaxine has minimal interaction with CYP450 enzymes, reducing the chances of interaction with antiretroviral drugs; however, when used alongside ritonavir, its dose should be decreased. 157 The metabolism of bupropion is interfered by ritonavir, efavirenz, and nelfinavir. 158, 159 A small study reported good tolerance of reboxetine in HIV patients. 160 
Psychostimulants
In an observational study, depressed PLWHA were randomly assigned to two groups and treated with either desipramine or methylphenidate. Treatment response was observed in 40% and 43% of subjects, respectively. 161 A similar study reported that 73% of those assigned to dextroamphetamine responded to treatment. 162 A specific indication for psychostimulants is neglect of self-care and nutrition in advanced HIV patients. 161, 162 Hormonal therapies Testosterone is reduced in HIV infection, and this may lead to anorexia, anergia, depression, and sexual dysfunction. Based on this hypothesis, hormonal therapies have been advocated to treat depression in PLWHA with some success. 163 However, this type of therapy is likely to be useful in PLWHA with decreased testosterone level.
Nonpharmacological interventions
Various techniques and interventions employed in a depressed population were studied in PLWHA. The major interventions employed were cognitive behavior therapy (CBT), interpersonal therapy (IPT), supportive psychotherapy, cognitivebehavioral-oriented group psychotherapy, experiential group psychotherapy, cognitive-behavioral stress management (CBSM), stress management interventions, cognitive remediation therapy, mindfulness-based therapy, and aerobic and resistance exercise. 
Cognitive behavior therapy
There is considerable evidence in the form of randomized controlled studies, meta-analysis, and systematic analysis attesting the efficacy of CBT in treating anxiety and depressive disorders in PLWHA. [164] [165] [166] A study by Lee et al 164 evaluated the feasibility and effectiveness of group CBT in combination with medication in 13 patients with HIV and depression. The authors found an overall positive response in terms of improvement in depression, and cognitive restructuring was the most helpful psychotherapeutic process of CBT. In a meta-analysis of 15 controlled trials, significant effects were found for improving symptoms of depression (d=0.33), anxiety (d=0.30), anger (d=1.00), and stress (d=0.43). 165 Similarly, a recent systemic review including 2,173 participants from 20 studies suggested that cognitive-behavioral intervention may be effective in the treatment of depression and anxiety in individuals living with HIV/AIDS. Effect sizes ranged from 0.02 to 1.02 for depression and 0.04 to 0.70 for anxiety. 166 
Interpersonal therapy
A randomized clinical trial reported that IPT resulted in significantly lower scores on the Hamilton Rating Scale for Depression (HAM-D) and the Beck Depression Inventory (BDI) compared to supportive psychotherapy. 167 Another randomized controlled trial involved randomly assigning 101 PLWHA with clinical depression and score 15 on the HAM-D to various treatment modalities. Results indicated that a significantly greater reduction in HAM-D scores occurred after IPT and supportive psychotherapy plus imipramine compared to CBT and supportive psychotherapy without imipramine. 168 
Supportive psychotherapy
Supportive psychotherapy was primarily based on teaching coping skills. A comparative study of CBT and supportive therapy reported clinically significant changes in depression in both groups, which were maintained at follow-up after 3 months. An important finding was that the occurrence of unprotected anal intercourse was reduced after supportive therapy. 167 
Cognitive-behavioral-oriented group psychotherapy
Two small studies found cognitive-behavioral-oriented group psychotherapy to be effective in improving psychosocial adjustment and reducing psychological distress in PLWHA. 169, 170 Experiential group psychotherapy A randomized study comparing the effects of experiential group psychotherapy and cognitive-behavioral group psychotherapy on asymptomatic homosexual PLWHA concluded that, while both therapies reduced psychological distress, there was no significant difference between the two therapies. 170 
Cognitive-behavioral stress management
A few studies have reported significant reductions in depression, [171] [172] [173] [174] [175] improved immune control of latent HSV-2 virus, 174 and reduced urinary cortisol levels after CBSM. 174, 175 The reduction in depression was directly related to reduction in cortisol levels in urine. 174, 175 CBSM training of PLWHA taking cART reduces anxiety and depression 176, 177 and improves global psychological functioning 180 and QoL 176,177 but does not improve surrogate markers of HIV-1 and self-reported adherence to therapy. 176 
Stress management interventions
A meta-analysis revealed that, in PLWHA, stress management resulted in significant improvements in anxiety, depression, distress, fatigue, and QoL, but had no effect on immune function (CD4 + counts and viral load) or hormone functions, indicating the need for further studies. 178 A recent study concluded that, while both group stress management and group CBT were effective in PLWHA, the former was more effective than the latter to decrease depression and anxiety. 179 
Cognitive remediation therapy
In addition to anxiety and depression, PLWHA continue to have cognitive impairments despite receiving cART. These cognitive and emotional impairments adversely affect occupational and driving performance, contribute to poor emotional processing, increase cognitive complaints, reduce QoL, and increase caregiver burden. Speed-of-processing training, a type of cognitive remediation therapy, may help to improve cognitive performance on measures of visual attention, speed of processing, and timed-task performances. A few studies also suggest that speed-of-processing training could also improve mood functions (depression and anxiety). The benefits of the improvement in these cognitive and emotional systems are a decrease or slowing in cognitive decline along with the potential to protect against clinically significant depressive symptoms. Further investigation into the benefits of this type of training as a behavioral adjunct for the pharmacologically burdened HIV population is needed. 180 Neurobehavioral 
Mindfulness-based therapy
Mindfulness-based treatment improves the well-being and QoL of PLWHA. In addition, it contributes to enhanced immunity, telomerase activity, and plasma levels of serotonin and melatonin. At the same time, it diminishes autonomic nervous system reactivity. 181 Aerobic and resistance exercise Exercise produces beneficial physiological changes and also reduces depression and anxiety in PLWHA. 182
Conclusion
There is enormous variation in the reported prevalence rates of depression, which ranges from 16% to 72%, and in the prevalence for anxiety, which ranges from 16% to 47%, among HIV patients. Various factors associated with and causative for this wide variation across studies include sample composition, diagnostic issues, different rating scales, gender of the patients, staging of HIV illness, etc. Moreover, depression increases the morbidity of HIV by poor adherence to treatment and various other significant mechanisms. Early identification and effective management of these disorders improves the QoL and adherence to ARV in PLWHA. Different treatment modalities including pharmacological and nonpharmacological psychotherapies have been used for the management of depression and anxiety in PLWHA. BZDs are indicated for short periods of time. Clonazepam and lorazepam are safe in terms of drug-drug interactions and may be preferred. SSRI are safer than TCAs. While differences in the efficacy of various SSRIs have not been established, to avoid interactions with ARVs, the better options are sertraline, citalopram, and escitalopram. Nonpharmacological therapies, including various psychotherapies and aerobic and resistance exercises, are effective in treating depression among PLWHA. However, definitive evidence to decide which nonpharmacological intervention is most beneficial for the management of depression in PLWHA is still awaited.
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